Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | GPR142 | Q7Z601 | 6/20 | 0.44 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13300080 | 1.00 | CTSV (0.51) | CTSVCTSLCTSBCTSSHDAC8 | |
| SCHEMBL3338335 | 0.84 | CTSV (0.46) | CTSVCTSLCTSBCTSSHDAC8 | |
| SCHEMBL14041575 | 0.83 | ULK1 (0.52) | CTSVCTSLCTSBCTSSHDAC8 | |
| SCHEMBL3330922 | 0.83 | HDAC8 (0.43) | HDAC8 | |
| SCHEMBL13300082 | 0.82 | CTSS (0.47) | CTSVCTSLCTSBCTSSHDAC8 | |
| SCHEMBL4428623 | 0.79 | CTSV (0.49) | CTSVCTSLCTSBCTSSHDAC8 | |
| SCHEMBL23213820 | 0.77 | PORCN (0.49) | CTSVCTSLCTSBCTSSLRRK2 | |
| SCHEMBL3332467 | 0.76 | CTSL (0.60) | CTSVCTSLCTSBCTSSHDAC8 | |
| SCHEMBL6672410 | 0.75 | NPC1 (0.53) | — | |
| SCHEMBL2302822 | 0.75 | HDAC8 (0.40) | CTSVCTSLCTSBCTSSHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | claimed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | PI4KB, AKT3, AKT2 | CTSV 2192/4885CTSL 1703/4885CTSB 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.